2014
2012
2015
2013
®
Listed on the Mainboard of Singapore Exchange
Securities Trading Limited (“SGX-ST”).
®
Received runner-up award as the Most Transparent
Company (New Issues category) at the Securities
Investors Association (Singapore) Investors’ Choice
Awards.
®
Acquired 10.02%* of China Cord Blood Corporation
(“CCBC”), China’s largest cord blood banking operator
which is listed on the New York Stock Exchange.
®
Extended strategic alliance and cooperation with
Cordlabs Asia Pte. Ltd. and CCBC for the provision
of cord lining banking services to certain territories
in China.
®
Entered into licensing agreement with StemLife for
the development of cord lining banking services in
Malaysia.
®
Launched Metascreen in the Philippines, Hong Kong
and Indonesia.
®
Launched Cord Blood Network, a programme to assist
Cordlife’s clients in the search for a matching cord
blood unit for three generations of the family, from
Cord Blood Network members.
®
Entered into memorandum of understanding with
CCBC as a Cord Blood Network member.
®
Launched cord lining banking services in Indonesia.
®
Completed acquisition of CCBC convertible note
for US$44 million. Assuming full conversion of the
note, Cordlife will hold approximately 17.79% of the
enlarged share capital of CCBC.
®
Cordlife moved to its fully-owned 23,000 square feet
office and laboratory facility in Singapore for storage
of up to 650,000 cord blood and cord lining units.
®
First in Asia to upgrade to SEPAX®2, a fully automated
Swiss-made cord blood processing system.
®
First to launch cord lining banking services in
Singapore and the Philippines.
®
Completed acquisition of cord blood and cord lining
banking businesses and assets in India, Indonesia,
Hong Kong and the Philippines from Life Corporation
Limited (“LCL”).
®
Cordlife’s India facility was accredited by American
Association of Blood Banks (“AABB”) and Cordlife’s
facilities in Singapore and Hong Kong successfully
passed re-accreditation audits by AABB.
®
Received Merit Award from Singapore Corporate
Awards under the Best Investor Relations: First-Year
Listed Companies category.
®
Acquired 19.92% stake in StemLife Berhad (“StemLife”),
a company listed on the ACE Market of Bursa Malaysia.
Investment was subsequently increased to 31.81% of
the issued and paid-up share capital in StemLife.
®
Launched Metascreen in India.
®
Received the Most Transparent Company Award (Retail
& Household category) at the Securities Investors
Association (Singapore) Investors’ Choice Awards.
®
Selected as one of the Best “Under A Billion”
Companies by Forbes Asia.
* Cordlife’s interest in CCBC has subsequently decreased to 9.13% as a result of an issuance of restricted share units to selected members of the CCBC management team.
2
CORDLIFE GROUP LIMITED
| ANNUAL REPORT 2015
MILESTONES
